Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: the eagle who wrote (685)	2/17/1998 7:52:00 PM
From: adam hefian	Read Replies (1) \| Respond to of 1826

Up only 9/16 on an FDA approval.Could have certainly done much better,at least up 1.5. Now we are back to 4 again,until next year.

To: the eagle who wrote (685)	2/17/1998 8:12:00 PM
From: David Cathcart	Read Replies (2) \| Respond to of 1826

Eagle, <<assuming, a europe partner then what do they get out of the deal---marketing rights?. have they entered into any other deals for other parts of the world?>> A European partner would get European marketing rights for MGI 114 and MGI Pharma would get a lot of money and a high profile endorsement of the drug. Rights for Japan were sold to Dainippon a few years ago for 12 million and that was before MGI 114 had even entered phase I trials. Unless Dainippon grossly overpaid for the Japanese rights, the rights for Europe should be worth much more today. If you believe that Blitzer will do what he says is a lock, MOGN remains an incredible bargain. David